CSDX
CS Diagnostics Corp.0.2300
-0.0190-7.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
57.50MP/E (TTM)
-Basic EPS (TTM)
-1257128.50Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
CS Diagnostics posted Q3 revenue of $23,050, up sharply y/y from $7,964 yet down q/q within a nine-month total of $94,200 (down 11% y/y per MD&A). Operating expenses held steady at $23,232, delivering a slim operating loss of $182 versus prior-year profit of $536; nine-month net income hit $32,081 on 32% expense cuts, mainly lower professional fees. Cash dwindled to $13, with net operating cash use of $528; no debt, but liquidity hinges on shareholder infusions amid going concern warnings. Issued Series C preferred shares. Expenses barely budged.
8-K
Preferred shares converted to common
CS Diagnostics Corp. completed the conversion of all outstanding Series B Preferred Stock held by affiliates CS Interpharm and CS Diagnostics Pharma into 112,652,000 common shares on October 30, 2025. This move simplifies the capital structure, eliminating preferred dividends while preparing for consolidated financial reporting by December 31, 2025. Affiliates now hold common stock directly, boosting alignment with shareholders. Yet consolidation integrates their revenues into CSDX's statements for a fuller performance view. Resales remain restricted under Rule 144.
10-Q
Q2 FY2025 results
CS Diagnostics swung to Q2 operating income of $196 from $4,349 y/y, yet revenue plunged 98% to $730 (derived) from one-time licensing deals, while H1 revenue fell 28% to $71,150 with expenses slashed over 50% to $38,887. Net income doubled to $32,263 on cost cuts, matching operating profit with no other items; EPS held at $0.00 across 137M diluted shares. Cash dipped to $196, but zero debt bolsters the balance sheet alongside $499.4M intangibles. Issued Series C preferred shares. Cash stays razor-thin.
8-K
CS Diagnostics unveils hydrogel innovation
CS Diagnostics Corp. spotlighted its role in the CS Group, emphasizing innovative medical distribution for patient care. The company highlights CS Protect Hydrogel, a spacer gel that separates healthy from malignant tissues in radiation therapy, boosting recovery odds for prostate cancer patients while enhancing safety and quality of life. Future products undergo rigorous testing. Its global reach aids regulatory approvals and collaborations worldwide.
10-K
FY2008 results
FlashZero Corp., formerly The Children's Internet, Inc., reported no revenue for FY2008 ended December 31, 2008, down from $664 in 2007, amid a development-stage halt in operations after taking its child-safe internet service offline in January 2008 to cut costs. The net loss narrowed to $401,629 from $1,165,988 year-over-year, driven by a 68% drop in general and administrative expenses to $355,195, while operating cash burn reached $727,607. Q4 showed no quarterly breakdowns, but the full-year trend reflected suspended sales and minimal activity, with shares outstanding rising to 48,286,306 from 31,373,738 via issuances for services and debt extinguishment. Liquidity remained tight at $37,381 in cash against $1.6 million in liabilities, funded by $742,463 in financing inflows. No annual guidance was provided. Ongoing SEC litigation over alleged investor fraud poses a key risk to any operational restart.
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
CDIX
Cardiff Lexington Corporation
1.42-0.29
CERS
Cerus Corporation
2.16+0.15
CODX
Co-Diagnostics, Inc.
0.25-0.02
CTSO
Cytosorbents Corporation
0.64+0.01
HSDT
Solana Company
3.10+0.06
LUCD
Lucid Diagnostics Inc.
1.12+0.01
SRDX
Surmodics, Inc.
42.98+0.00
SSMXF
Sysmex Corp.
9.33+0.00
WGS
GeneDx Holdings Corp.
141.72-8.89